PubMed Health⌕ Search

Biomedical subjects

Tatsuo Yamakawa

Publications and source records attributed to Tatsuo Yamakawa.

4 recordsLinked to original sources
PubMed2005

[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].

HCFU and UFT were reported effective in adjuvant chemotherapy for colorectal cancer. This investigation was planned as a randomized study to compare the usefulness of combination therapies with mitomycin C (MMC)+HCFU and MMC+UFT as postoperative adjuvant chemotherapy in patients with colorectal cancer following curative resection, in terms of survival rate, recurrence rate, and adverse drug reactions. A total of 501 patients consisting of 252 patients with stage III/IV colon cancer (Colorectal Cancer Handling Rules, 4th Ed.) for which macroscopic curative resection was possible and 249 patients with stage II/III/IV rectal cancer (ibid, 4th Ed.) were registered from 40 participating institutions. The patients were randomly allocated to two groups with colon cancer and rectal cancer employed as stratification factors. Beginning on Day 14 after surgery, HCFU at 300 mg/day was administered to one group and UFT at 300 mg/day or 400 mg/day to another group, both orally and daily for one year. MMC 6 mg/m2 was administered intravenously to both groups on the day of surgery and the day following. Among the 501 patients, 496 patients (99%) were eligible. The 5-year survival rates were 77.1% for the MMC+ HCFU group and 79.2% for the MMC+UFT group, with the 5-year recurrence-free survival rates were 76.1% and 72.9%, respectively, neither showing a significant difference between the groups. Adverse drug reactions appeared in 23% of patients in the MMC+HCFU group and in 19% in the MMC+UFT group, with no serious reactions. One year after surgery the administration completion rates were good, at 82% for the MMC+HCFU group and 83% for the MMC+UFT group. No clear difference in effectiveness was noted between MMC+HCFU therapy and MMC+UFT therapy as postoperative adjuvant chemotherapy for colorectal cancer. The administration completion rates were good, and no serious adverse drug reactions were observed for either therapy. It was thus considered that both therapies could be administered safely, and both were useful as postoperative adjuvant chemotherapies for colorectal cancer. It is considered necessary to compare them with standard therapies in Western countries in the future.

Adenocarcinoma↗
PubMed2002

[Expression of Fas and induction of apoptosis by anti-Fas monoclonal antibody in human bile duct carcinoma cells, and enhancement of induction of apoptosis by IFN-gamma].

We investigated the expression of Fas, the induction of apoptosis by anti-Fas monoclonal antibody CH-11, and the effect of IFN-gamma on the induction of apoptosis in human bile duct carcinoma cells HuCCT1 and HuH28. Fas was expressed in 21.7% and 30.9% of HuCCT1 and HuH28 cells, respectively. Pretreatment with IFN-gamma increased the Fas expression by 17.6% in HuCCT1 cells. However, IFN-gamma did not affect the expression of Fas in HuH28 cells. In HuCCT1 and HuH28 cells treated with CH-11, the peak corresponding to that of positive control cells was detected with the TUNEL method by FCM. The condensation and fragmentation of the nucleus, and the apoptotic body were observed as morphological changes specific to apoptosis. CH-11 dose-dependently reduced HuCCT1 and HuH28 cell counts by up to 16.4% and 71.7%, respectively on day 3. Interferon-gamma attenuated the reduction of HuCCT1 cell counts by 12.8% on day 3. However, IFN-gamma had no effect on HuH28 cell counts. These results suggest that Fas was expressed, apoptosis was induced by CH-11 and the induction of apoptosis was enhanced by IFN-gamma in human bile duct carcinoma cells.

Antibodies, Monoclonal↗
PubMed2002

[Evaluation of the diagnostic efficacy of SPIO enhanced MRI in patients with focal hepatic lesions--comparison with CECT and CTAP].

The aim of this study was to compare the diagnostic efficacy of superparamagnetic iron oxide (SPIO)-enhanced MRI for the detection and diagnostic accuracy of focal liver lesions with helical contrast enhanced CT (CECT) and CT during arterial portography (CTAP). Thirty-nine patients (25 men and 14 women, mean age 63.5 years) were examined by SPIO-MRI and triple-phase CECT. Eleven of them were also examined by CTAP. There were a total of 96 confirmed focal hepatic lesions, 61 metastatic cancers in 18 patients and 35 hepatocellular carcinomas (HCCs) in 21 patients. Final diagnosis was established by operation in 25 cases, by biopsy in 7 cases, and by progression of disease on follow-up examination in the other 7 cases. The sensitivity of SPIO-MRI for HCC detection was almost equal to CECT, but that of SPIO-MRI for metastatic cancer detection, especially cancers smaller than 1 cm in size, was significantly superior to CECT. The sensitivity of SPIO-MRI for both HCC and metastatic cancer detection was almost equal to that of CTAP, but the specificity of SPIO-MRI for detection of both lesions was significantly superior to that of CTAP because CTAP produced a higher incidence of false-positive findings. In conclusion, SPIO-MRI could take the place of CTAP as a non-invasive excellent modality to determine the distribution of hepatic lesions preoperatively. SPIO-MRI could also be a useful modality to follow liver metastasis postoperatively in patients with advanced digestive cancers.

Carcinoma, Hepatocellular↗